SPONSOR
Akeso
Total Trials
9
Recruiting
9
Phases
Phase 1, Phase 2, Phase 1, Phase 3, Phase 2
Conditions studied: Advanced Solid TumorSolid TumorGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaNon-Small Cell Lung CancerTriple-Negative Breast Cancer (TNBC)Resectable Colon CancerMSI-H/dMMR Colorectal CancerBiliary Tract CancerRecurrent Ovarian CancerNSCLC (Non-small Cell Lung Cancer)
Akeso is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Advanced Solid Tumor, Solid Tumor, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Akeso
How many clinical trials has Akeso sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Akeso, of which 9 are actively recruiting participants. These trials cover conditions including Advanced Solid Tumor, Solid Tumor, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Akeso research focus on?
Akeso clinical trials span Advanced Solid Tumor, Solid Tumor, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Akeso clinical trial?
To participate in a Akeso trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Akeso trials with current recruitment status updated daily.
Clinical Trials by Akeso
NCT05142423 Phase 1, Phase 2
Recruiting
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
NCT06166888 Phase 1
Recruiting
A Study of AK131 in Patients With Advanced Solid Tumors
Solid Tumor
NCT07023315 Phase 3
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT07623356 Phase 1, Phase 2
Recruiting
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT06767527 Phase 3
Recruiting
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Triple-Negative Breast Cancer (TNBC)
NCT07412613 Phase 3
Recruiting
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Resectable Colon Cancer
NCT06938321 Phase 1, Phase 2
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Biliary Tract Cancer
NCT06560112 Phase 2
Recruiting
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Recurrent Ovarian Cancer
NCT06617416 Phase 3
Recruiting
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
NSCLC (Non-small Cell Lung Cancer)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology